中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (9): 808-815.doi: 10.35541/cjd.20240733

• 论著·色素性皮肤病 • 上一篇    下一篇

上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析

徐中奕    邢小雪    董雅琦    张成锋    项蕾红   

  1. 复旦大学附属华山医院皮肤科,上海  200040
  • 收稿日期:2024-12-31 修回日期:2025-07-13 发布日期:2025-09-01
  • 通讯作者: 项蕾红 E-mail:flora_xiang@vip.163.com
  • 基金资助:
    国家重点研发计划(2023YFC2509001)

Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai

Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong   

  1. Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
  • Received:2024-12-31 Revised:2025-07-13 Published:2025-09-01
  • Contact: Xiang Leihong E-mail:flora_xiang@vip.163.com
  • Supported by:
    National Key Research and Development Program of China(2023YFC2509001)

摘要: 【摘要】 目的 分析影响黄褐斑严重程度的因素及评估不同治疗方法的疗效。方法 回顾分析2018年7月至2023年12月于复旦大学附属华山医院皮肤科色素病专病门诊诊断为黄褐斑患者的临床资料。由医生评估患者Fitzpatrick皮肤分型、皮损颜色、部位、分型,计算黄褐斑面积及严重程度评分(MASI),使用ΔMASI(基线MASI - 治疗后MASI)评价疗效。使用t检验和单因素方差分析进行黄褐斑严重程度的影响因素分析,使用配对t检验比较治疗前后MASI评分的差异,建立多因素线性回归模型分析影响黄褐斑疗效的因素。结果 纳入黄褐斑病例254例,年龄(40.8 ± 6.1)岁,女性249例(98.0%)。Fitzpatrick皮肤分型Ⅲ型213例(83.9%),Ⅳ型41例(16.1%);180例(70.9%)无涂抹防晒霜的习惯。根据色素所在位置,表皮型166例(65.4%),混合型88例(34.6%)。色斑发生部位,颊型174例(68.5%),面中部型26例(10.2%),下颌型54例(21.3%)。有眶周受累者127例(50.0%)。治疗前Fitzpatrick皮肤分型Ⅳ型患者组MASI评分(x ± s,19.75 ± 5.08)高于Ⅲ型患者组(14.47 ± 4.18),无防晒习惯组(16.45 ± 4.61)高于有防晒习惯组(12.59 ± 3.91),色素为表皮型组(15.99 ± 4.82)高于混合型组(14.07 ± 4.35),色斑部位为下颌型组(18.37 ± 5.14)高于面中部型组(14.23 ± 3.46)和颊型组(14.54 ± 4.40),存在眶周受累组(16.54 ± 4.90)高于无眶周受累组(14.10 ± 4.26),且差异均有统计学意义,均P < 0.001。主要治疗方案分为外用2%氢醌组(109例,每晚外用2%氢醌乳膏1次)、外用非氢醌类美白制剂组(36例,外用除氢醌乳膏以外的其他美白或剥脱剂)、口服氨甲环酸组(50例,口服氨甲环酸片250 mg每日2次)、果酸化学剥脱术组(30例,每月1次浓度从20% ~ 50%逐渐递增的果酸剥脱治疗)。4组患者治疗后MASI评分均低于治疗前(均P < 0.001),外用2%氢醌组、外用非氢醌类美白制剂组、口服氨甲环酸组、果酸化学剥脱术组ΔMASI值分别为1.65 ± 2.19、1.40 ± 2.16、4.58 ± 3.09、3.39 ± 3.61,差异有统计学意义(F = 17.40, P < 0.001 ),口服氨甲环酸组和果酸化学剥脱术组的疗效显著优于外用2%氢醌组和外用非氢醌类美白制剂组(均P < 0.05),口服氨甲环酸组与果酸化学剥脱术组的疗效差异无统计学意义(P > 0.05)。多元线性回归模型显示,调整潜在混杂因素后,口服氨甲环酸组(β = 2.64)和果酸化学剥脱术组(β = 1.55)的疗效依旧显著优于外用2%氢醌组(均P < 0.05);Fitzpatrick皮肤分型Ⅳ型患者的疗效显著优于Ⅲ型患者(β = 1.87,P < 0.001)。结论 深肤色、无防晒习惯、表皮型黄褐斑、下颌型黄褐斑、存在眶周受累是黄褐斑严重程度较高的相关因素;口服氨甲环酸、果酸化学剥脱术治疗黄褐斑的疗效优于外用2%氢醌和外用非氢醌类美白制剂。

关键词: 黄褐斑, 临床分型, 疾病严重程度指数, 影响因素, 治疗, 氨甲环酸, 化学剥脱术, 治疗结果, 黄褐斑面积及严重程度评分

Abstract: 【Abstract】 Objective To analyze factors influencing the melasma severity, and to evaluate the efficacy of different treatment modalities. Methods A retrospective analysis was conducted on clinical data from patients diagnosed with melasma at the Pigmentary Disorders Specialty Clinic in the Department of Dermatology, Huashan Hospital, Fudan University from July 2018 to December 2023. Patients' Fitzpatrick skin types, lesion color, locations and subtypes were evaluated by dermatologists, the melasma area and severity index (MASI)scores were calculated, and ΔMASI scores (baseline MASI scores - post-treatment MASI scores) were used for efficacy evaluation. The t test and one-way analysis of variance were used to analyze factors influencing the severity of melasma, the paired t test was used to analyze the differences in MASI scores before and after treatment, and a multivariate linear regression model was established to analyze factors influencing the efficacy in the treatment of melasma. Results A total of 254 patients (including 249 females, 98.0%) with melasma were included, with ages of 40.8 ± 6.1 years. The Fitzpatrick skin type was Ⅲ in 213 (83.9%) patients, and Ⅳ in 41 (16.1%) patients; 180 (70.9%) patients lacked the habit of using sunscreens regularly. According to the location of pigment deposition?, 166 cases (65.4%) were classified as epidermal type, and 88 (34.6%) as mixed type. Pigmented lesions were located on the cheek (174 cases, 68.5%), midface (26 cases, 10.2%), or lower jaw (54 cases, 21.3%), with periorbital involvement observed in 127 cases (50.0%). Before treatment, baseline MASI scores were significantly higher in the skin type Ⅳ group (19.75 ± 5.08) than in the skin type Ⅲ group (14.47 ± 4.18, P < 0.001), in the non-sunscreen users (16.45 ± 4.61) than in the sunscreen users (12.59 ± 3.91, P < 0.001), in the epidermal type group (15.99 ± 4.82) than in the mixed type group (14.07 ± 4.35, P < 0.001), in the mandibular type group (18.37 ± 5.14) than in the midfacial type group (14.23 ± 3.46, P < 0.001) and malar type group (14.54 ± 4.40, P < 0.001), as well as in the patients with periorbital involvement (16.54 ± 4.90) than in those without (14.10 ± 4.26, P < 0.001). According to the main treatment regimens, the patients were divided into the topical 2% hydroquinone group (109 cases, topically treated with 2% hydroquinone cream nightly), topical non-hydroquinone skin-lightening agents group (36 cases, topically treated with non-hydroquinone skin-lightening or exfoliating agents), oral tranexamic acid group (50 cases, treated with oral tranexamic acid 250 mg twice daily), and alpha hydroxy acid (AHA) chemical peeling group (30 cases, receiving AHA chemical peeling treatment monthly with the AHA concentration escalating from 20% to 50%). After treatment, MASI scores were significantly reduced from baseline in all the 4 groups (all P < 0.001), and the ΔMASI values significantly differed among the topical 2% hydroquinone group, topical non-hydroquinone skin-lightening agents group, oral tranexamic acid group, and AHA chemical peeling group (1.65 ± 2.19, 1.40 ± 2.16, 4.58 ± 3.09, 3.39 ± 3.61, respectively, F = 17.40, P < 0.001). The oral tranexamic acid group and AHA chemical peeling group showed significantly superior efficacy compared to the topical 2% hydroquinone group and topical non-hydroquinone skin-lightening agents group (all P < 0.05), while there was no significant difference in the efficacy between the oral tranexamic acid group and the AHA chemical peeling group (P > 0.05). After adjustment for potential confounders in the multivariate linear regression model, the oral tranexamic acid group (β = 2.64) and AHA chemical peeling group (β = 1.55) still showed significantly superior efficacy compared to the topical 2% hydroquinone group (both P < 0.05); the skin type Ⅳ group exhibited significantly superior efficacy compared to the skin type Ⅲ group (β = 1.87, P < 0.001). Conclusions Dark skin color, lack of sun protection habits, epidermal melasma, and mandibular-type melasma, and periorbital involvement were associated factors for the severity of melasma. Oral tranexamic acid and AHA chemical peeling appeared to exhibit superior efficacy compared to topical 2% hydroquinone cream and topical non-hydroquinone skin-lightening agents.

Key words: Chloasma, Clinical types, Severity of illness index, Influencing factors, Therapy, Tranexamic acid, Chemexfoliation, Treatment outcome, Melasma area and severity index

引用本文

徐中奕 邢小雪 董雅琦 张成锋 项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025,58(9):808-815. doi:10.35541/cjd.20240733

Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong. Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai[J]. Chinese Journal of Dermatology, 2025, 58(9): 808-815.doi:10.35541/cjd.20240733